Turn Therapeutics (NASDAQ:TTRX) Upgraded at WBB Securities

Turn Therapeutics (NASDAQ:TTRX) was upgraded by WBB Securities from a “sell” rating to a “hold” rating in a research note issued to investors on Friday, Benzinga reports. The brokerage currently has a $10.00 price target on the stock. WBB Securities‘s target price points to a potential downside of 1.77% from the company’s previous close.

TTRX has been the subject of a number of other reports. LADENBURG THALM/SH SH raised Turn Therapeutics to a “strong-buy” rating in a report on Monday, July 20th. Weiss Ratings cut Turn Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, August 18th. Zacks Research raised shares of Turn Therapeutics to a “hold” rating in a research note on Tuesday, July 21st. Lucid Cap Mkts upgraded shares of Turn Therapeutics to a “strong-buy” rating in a report on Thursday, September 24th. Finally, Wall Street Zen cut shares of Turn Therapeutics from a “hold” rating to a “sell” rating in a research note on Sunday, October 18th. Two research analysts have rated the stock with a Strong Buy rating, one has issued a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $9.00.

Turn Therapeutics Trading Up 0.3%

Shares of TTRX opened at $10.18 on Friday. The company has a debt-to-equity ratio of 8.83, a current ratio of 1.19 and a quick ratio of 1.19. Turn Therapeutics has a 1-year low of $2.57 and a 1-year high of $16.45. The stock has a market cap of $310.80 million and a price-to-earnings ratio of -35.10. The firm has a 50 day simple moving average of $11.63 and a 200-day simple moving average of $8.13.

Turn Therapeutics (NASDAQ:TTRX) last posted its earnings results on Wednesday, August 12th. The company reported ($0.20) earnings per share (EPS) for the quarter. Equities analysts forecast that Turn Therapeutics will post -0.40 EPS for the current fiscal year.

Hedge Funds Weigh In On Turn Therapeutics

Hedge funds have recently made changes to their positions in the stock. SteelPeak Wealth LLC grew its stake in shares of Turn Therapeutics by 0.7% during the 3rd quarter. SteelPeak Wealth LLC now owns 251,275 shares of the company’s stock valued at $3,616,000 after buying an additional 1,819 shares during the period. TD Waterhouse Canada Inc. acquired a new stake in shares of Turn Therapeutics during the 3rd quarter worth $40,000. Jefferies Financial Group Inc. acquired a new stake in shares of Turn Therapeutics during the 2nd quarter worth $119,000. Bank of America Corp DE purchased a new position in shares of Turn Therapeutics in the 2nd quarter worth $103,000. Finally, Ieq Capital LLC acquired a new position in Turn Therapeutics in the second quarter valued at $1,660,000.

About Turn Therapeutics

Turn Therapeutics, Inc is a biotechnology and pharmaceutical company focused on developing topical therapies for skin and wound-care applications. The company’s platform is designed to support the delivery of therapeutic compounds to the skin while helping address microbial contamination and other complications associated with wounds.

Turn Therapeutics has identified MVT-100 as a lead product candidate. The topical formulation is intended for use in wound-care settings, including the management of chronic and difficult-to-heal wounds.